ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

심볼 ABBVON

순위 No.3317

시가총액 $0.00

완전히 희석된 시가총액 $0.00

시장 점유율 %

거래량/시가총액 (24시간) 960,454.06%

유통 공급량 123.08541488

최대 공급량 0

총 공급량 123.08541488

유통률 %

발행일 --

자산이 처음 발행된 가격 --

사상 최고가 237.64005999136555, 2026-03-05

최저가 193.3720963640878, 2026-04-29

퍼블릭 블록체인 ABBVON

소개 AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

섹터

SNS

• Twitter

• 공식 웹사이트
• 블록 탐색기

자금 흐름 분석

etfindex:mc_etfindex_source 면책 조항: cmc에서 제공한 데이터는 투자 조언으로 간주되어서는 안 됩니다.